1. Mohagheghi M, Moosavi JA, Shariat TS: Annual report of Tehran University of Medical Sciences, District cancer registry in 1997.
2. Hrafnkelsson J, Tulinius H, Sigvaldson H. Familial nonmedullary thyroid cancer in Iceland. Journal of Medical Genetic 2001;38:189-91.
3. Drake RL, Vogl W, itchell AWM, ray H. Gray's anatomy for students. 2nd ed. Philadelphia: Churchill Livingstone/Elsevier; 2014.
4. Deandrea M, Gallone G, Veglio M. Thyroid cancer hystotype changes as observed in a major generalHospital in a 21 year period. Journal of Endocrinology Investigation 1997; 20:52-8.
5. Rosai J, Tallini G. Rosai and Ackerman's surgicalpathology. 10th ed. New York: Mosby; 2011.
6. Choi D, Hwang S, Lee E. Expression of mitochondria dependent apoptosis genes (p53, Bax, Bcl-2) in rat granulosa cells during follicular development. Journal of the Society for Gynecologic Investigation 2004; 11:311-7.
7. Mitsiades N, Poulaki V, Kotoula V, Mastorakos G, Tseleni-Balafouta S, Koutras DA, et al. Fas/Fas ligand up-regulation and Bcl-2 downregulation may be significant in the pathogenesis of Hashimoto’s thyroiditis. The Journal of Clinical Endocrinology & Metabplism. 1998: 83:2199–203.
8. Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clinical Cancer Research. 2005: 11:3958–65.
9. Aksoy M, Giles Y, Kapran Y, Terzioglu T, Tezelman S. Expression of bcl-2 in Papillary Thyroid Cancers and its Prognostic Value. Actachirbelg 2005; 105: 644-8.
10. Dinets A, Hulchiy M, Sofiadis A, Ghaderi M, Höög A, Larsson C, etal. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma. European Journal of Endocrinology. 2012;166(6):1049-60.
11. Longo D L, Fauci AS, Kasper DL, Hauser StL, Jameson JL ,Loscalzo J. Harrison's principles of internal medicine. 18thed, New York: McGraw hill; 2012.
12. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di LibertoD,Patti M, etal. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Research. 2003; 63(20):6784-90.
13. Siironen P, Nordling S, Louhimo J, Haapiainen R, Haglund C.Immunohistochemical expression of Bcl-2, Ki-67, and p21 in patients with papillary thyroid cancer. Tumour Biology. 2005 ; 26(1):50-6.
14. Manetto V, Lorenzini R, Cordon-Cardo C, Krajewski S, Rosai J, Reed JC, et al. Bcl-2 and Bax expression in thyroid tumours. An immunohistochemical and western blot analysis. Virchows Archives. 1997; 430(2):125-30.
15. Aksoy M, Giles Y, Kapran Y, Terzioglu T, Tezelman S. Expression of bcl-2 in papillary thyroid cancers and its prognostic value. Acta Chirurgica Belgica. 2005; 105(6):644-8.
16. Soda G, Antonaci A, Bosco D, Nardoni S, Melis M. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas. Journal of Experimental & Clinical Cancer Research 1999; 18(3):363-7.
)